Use of beta-adrenoceptor antagonists for the manufacture of a medicament of the treatment of disorders of the outer retina

A method of inducing endogenous production of neurotrophic factors in an eye of a patient having a disorder of the outer retina, comprising delivering an ophthalmic composition comprising a β-adrenoceptor antagonist to the eye, wherein the β-adrenoceptor antagonist is timolol, carteolol, levobunolol, metipranolol, befunolol, propranolol, metoprolol, atenolol, pendolol, or pinbutolol, wherein the disorder of the outer retina is ARMD;

• RP;
• retinal detachment, retinal tear, macular pucker;
• ischemia affecting the outer retina;
• damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT);
• trauma;
• surgical (retinal translocation, subretinal surgery, or vitrectomy) or light induced iatrogenic retinopathy;
• or preservation of retinal transplants, wherein the ophthalmic composition comprises from 0.001% to 5% w/v of the β-adrenoceptor antagonist in a pharmaceutical acceptable carrier.